Lactobacillus reuteri: Research, Dosing, and Where to Buy in 2026
A research-first profile for Lactobacillus reuteri (L. reuteri), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Lactobacillus reuteri is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Lactobacillus reuteri, each linked to its source.
- Also indexed as L. reuteri.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Lactobacillus reuteri?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Lactobacillus reuteri Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Lactobacillus reuteri in 2026
No tracked vendor recommendations for Lactobacillus reuteri yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Lactobacillus reuteri. Each line links to the original source.
- "Irinotecan (CPT11)-induced diarrhea affects 80-90% of cancer patients due to β-glucuronidase (GUS) converting 7-ethyl-10-hydroxycamptothecin glucuronide (SN38G) to 7-ethyl-10-hydroxycamptothecin (SN38)." · Yue B et al, 2025 PubMed
Research and Studies
8 PubMed-indexed papers reference Lactobacillus reuteri. Top 8 shown.
Legal Status
Lactobacillus reuteri is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Lactobacillus reuteri FDA-approved?
Lactobacillus reuteri is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Lactobacillus reuteri?
8 PubMed-indexed paper(s) reference Lactobacillus reuteri in our current research feed. See the Research and Studies section above for citations.